MedTrace Logo

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

NCT04175522 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-06-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis

Conditions

  • Autoimmune Encephalitis

Interventions

DRUG

Immunoglobulin G

IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Soon Tae Lee, MD, Ph.D. · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2020-06-11
Completion
2020-06-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175522 on ClinicalTrials.gov